CSIMarket Company Name, Ticker, Suppliers, else..
 
Femasys Inc   (NASDAQ: FEMY)
 
Price: $2.9800 $-0.08 -2.614%
Day's High: $3.062999963760376 Week Perf: -13.12 %
Day's Low: $ 2.93 30 Day Perf: 1.02 %
Volume (M): 72,900 52 Wk High: $ 22.20
Volume (M$): $ 0 52 Wk Avg: $9.36
Open: $3.03 52 Wk Low: $2.02



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 3
 Employees 54
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 1

Business Description


Femasys Inc is a healthcare company based in Suwanee, Georgia, that focuses on developing innovative medical devices for women's health. The company specializes in creating non-surgical solutions for common gynecological procedures. Some of their products include the FemBloc Permanent Contraceptive System, which provides a non-hormonal, incision-less approach to tubal occlusion, and the FemVue Saline-Air Device, used to evaluate fallopian tube patency. Femasys Inc aims to improve women's healthcare by offering safe, effective, and minimally invasive solutions.


   Company Address: 3950 Johns Creek Court Suwanee 30024 GA
   Company Phone Number: 500-3910   Stock Exchange / Ticker: NASDAQ FEMY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLCO        5.19% 
ESTA        5.17% 
EYE   -3.68%    
MDT        3.22% 
MDXG        1.56% 
WST        0.74% 
• View Complete Report
   



Partnership

Femasys Inc. Enhances European Contraceptive Market with Record Growth and Strategic Partnerships

Published Mon, Nov 10 2025 3:41 PM UTC

In a significant stride toward enhancing women s health and reproductive rights, Femasys Inc. (NASDAQ: FEMY) has announced a notable initial order valued at approximately $500,000 USD for its innovative FemBloc Permanent Birth Control solution. This order, forged through a strategic partnership with Kebomed, a prominent distributor in France and the Benelux region, underscor...
Partnership

Femasys Innovates with Launch of FemSperm Analysis Kit A Leap Forward in Complete In-Office Sperm Handling and Reve...

Published Mon, Sep 22 2025 1:42 PM UTC

In an exciting development within the healthcare sector, Femasys Inc., a recognized leader specializing in innovative women s healthcare solutions, has announced a groundbreaking partnership with Medical Electronic Systems to launch the FemSperm Analysis Kit. This strategic move not only expands the portfolio of Femasys products but also enhances the capabilities of gynecolo...
Partnership

Femasys Expands Fertility Reach with Strategic Partnership, Positively Impacting Growth Trajectory

Published Wed, Jun 11 2025 1:43 PM UTC

In today’s evolving healthcare landscape, women s health, particularly in reproductive medicine, has emerged as a focal point of innovation and investment. Femasys, Inc. a prominent player in this sector, has recently bolstered its standing through a forward-thinking partnership with the Carolinas Fertility Institute (CFI), one of America s premier fertility clinics. This ...
Clinical Study

Femasys Inc. Celebrates Positive Results from Pivotal Trial of FemaSeed Infertility Treatment Amid Strong Financial P...

Published Tue, Nov 26 2024 1:30 PM UTC

Femasys Inc. an innovative leader in women’s health, has announced the successful peer-reviewed publication of data from its prospective, multicenter pivotal trial evaluating the FemaSeed infertility treatment. The trial results, garnering widespread attention, demonstrate both the safety and effectiveness of FemaSeed’s intratubal insemination procedure. High satisfactio...
Stock Market Announcement

Femasys Secures Patent for FemBloc Device, Paving the Way for Permanent Birth Control Solutions

Published Fri, Nov 1 2024 12:30 PM UTC

Femasys Inc. and the FemBloc Patent: A Significant Step ForwardFemasys Inc. a company committed to providing innovative solutions in women s healthcare, recently announced the issuance of a U.S. patent covering its FemBloc device, designed for female permanent birth control. This development is part of Femasys s broader mission to empower women by offering them more control...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.35
Price to Sales (Expected) -
Price to Book 2.48
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.37
Working Capital Ratio 2.14
Leverage Ratio (MRQ) 2.05
Total Debt to Equity 0.87
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.53 $
Revenues (TTM) 0.68 $
Cash Flow (TTM) -
Cash 0.43 $
Book Value 1.2 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 42,582
Net Income per Employee (TTM) -227,512
Receivable Turnover Ratio (TTM) 6.08
Inventory Turnover Ratio (TTM) 0.15
Asset Turnover Ratio (TTM) 0.07

Profitability Ratios Current
Gross Margin (MRQ) 57.08 %
Operating Margin (MRQ) -1526.66 %
Net Margin (MRQ) -1346.81 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Femasys Inc's Segments
US    208.43 % of total Revenue
International    19.58 % of total Revenue
Single Reportable Segment    228.01 % of total Revenue

  Femasys Inc Outlook

On March 28 2024 the Femasys Inc provided following guidance

Femasys Inc. has recently announced its financial r...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.